{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:44:13Z","timestamp":1792784653568,"version":"4.5.0"},"reference-count":101,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu","award":["SBAG-122S996"],"award-info":[{"award-number":["SBAG-122S996"]}],"id":[{"id":"https:\/\/ror.org\/04w9kkr77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu","award":["SBAG-218S682"],"award-info":[{"award-number":["SBAG-218S682"]}],"id":[{"id":"https:\/\/ror.org\/04w9kkr77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of targetable receptors and limited therapeutic options. Its inherently low immunogenicity necessitates strategies to enhance its susceptibility to immune attack. This study aimed to enhance the antitumor immune response by inducing downregulation of the programmed death ligand 1 (PD-L1), thereby increasing cancer cell recognition and activating tumor-specific immunity. To this end, a targeted solid lipid nanoparticle (tSLN) system was developed for the precise delivery of CRISPR\/Cas9 plasmids to achieve functional PD-L1 downregulation. The SLN formulation comprised a cetyl palmitate core stabilized with cationic and PEGylated lipids. Functionalization with the tumor-penetrating peptide iRGD yielded tSLN, which demonstrated good colloidal stability, serum protection of the CRISPR cargo, and minimal cytotoxicity. In vitro studies in two breast cancer subtypes, the luminal MCF-7 and the triple-negative 4T1 line, confirmed greater transfection efficiency and PD-L1 knockdown by tSLN:Crispr\/PD-L1 relative to non-targeted controls. In an orthotopic 4T1 mouse model, systemic administration of tSLN:Crispr\/PD-L1 significantly inhibited tumor growth and metastasis while enhancing T cell infiltration, and was more effective than standard chemotherapy (paclitaxel) in this model. The targeted approach also exhibited a favorable short-term safety profile, with no organ toxicity detected over the treatment period. These findings underscore the potential of SLN-mediated CRISPR delivery as an immunomodulatory strategy for breast cancer, and particularly for TNBC.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00750","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:02:19Z","timestamp":1788872539000},"page":"5069-5089","source":"Crossref","is-referenced-by-count":0,"title":["Reinforcement of Solid Lipid Nanoparticles for Targeted PD-L1 Downregulation in Breast Cancer"],"prefix":"10.1021","volume":"23","author":[{"given":"Deniz","family":"Onan","sequence":"first","affiliation":[{"name":"Ege University , , , ,","place":["Bornova, I\u0307zmir, Turkey, 35100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"O\u0308zder","sequence":"additional","affiliation":[{"name":"Ege University , , , ,","place":["Bornova, I\u0307zmir, Turkey, 35100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u0308ls\u0327ah","family":"Erel-Akbaba","sequence":"additional","affiliation":[{"name":"I\u0307zmir Katip Celebi University , , , ,","place":["C\u0327ig\u0306li, I\u0307zmir, Turkey, 35620"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"C\u0327ak\u0131rog\u0306lu","sequence":"additional","affiliation":[{"name":"I\u0307zmir Biomedicine and Genome Center , , ,","place":["Balc\u0327ova, I\u0307zmir, Turkey, 35340"]},{"name":"Dokuz Eylul University , , , ,","place":["Balc\u0327ova, I\u0307zmir, Turkey, 3534"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0327erif","family":"S\u0327entu\u0308rk","sequence":"additional","affiliation":[{"name":"I\u0307zmir Biomedicine and Genome Center , , ,","place":["Balc\u0327ova, I\u0307zmir, Turkey, 35340"]},{"name":"Dokuz Eylul University , , , ,","place":["Balc\u0327ova, I\u0307zmir, Turkey, 3534"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ays\u0327e Gu\u0308lten","family":"Kantarc\u0131","sequence":"additional","affiliation":[{"name":"Ege University , , , ,","place":["Bornova, I\u0307zmir, Turkey, 35100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-6346","authenticated-orcid":true,"given":"Hasan","family":"Akbaba","sequence":"additional","affiliation":[{"name":"Ege University , , , ,","place":["Bornova, I\u0307zmir, Turkey, 35100"]},{"name":"I\u0307zmir Biomedicine and Genome Center , , ,","place":["Balc\u0327ova, I\u0307zmir, Turkey, 35340"]},{"name":"Ege University , , , ,","place":["Bornova, I\u0307zmir, Turkey, 35100"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"1","key":"2026100509320552200_cit1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in Immunotherapy for Triple-Negative Breast Cancer [Review of Advances in Immunotherapy for Triple-Negative Breast Cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"2026100509320552200_cit2","doi-asserted-by":"publisher","first-page":"100450","DOI":"10.1016\/j.mtbio.2022.100450","article-title":"Nanomaterial-Assisted CRISPR Gene-Engineering \u2212 A Hallmark for Triple-Negative Breast Cancer Therapeutics Advancement","volume":"16","author":"Farheen","year":"2022","journal-title":"Mater. Today Bio"},{"key":"2026100509320552200_cit3","doi-asserted-by":"publisher","first-page":"115449","DOI":"10.1016\/j.bcp.2023.115449","article-title":"CRISPR\/Cas Genome Editing in Triple Negative Breast Cancer: Current Situation and Future Directions [Review of CRISPR\/Cas Genome Editing in Triple Negative Breast Cancer: Current Situation and Future Directions","volume":"209","author":"Fu","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"2026100509320552200_cit4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.17615\/3w4b-rf62","article-title":"Nanocarrier-Mediated Immunogenic Chemotherapy for Triple Negative Breast Cancer","volume":"323","author":"Liu","year":"2020","journal-title":"J. Control Release"},{"issue":"9","key":"2026100509320552200_cit5","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/biomedicines13092213","article-title":"Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential [Review of Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential","volume":"13","author":"Shatalov","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"2026100509320552200_cit6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","article-title":"Immunotherapeutic Interventions of Triple Negative Breast Cancer [Review of Immunotherapeutic Interventions of Triple Negative Breast Cancer","volume":"16","author":"Li","year":"2018","journal-title":"J. Transl. Med."},{"issue":"37","key":"2026100509320552200_cit7","doi-asserted-by":"publisher","first-page":"18295","DOI":"10.1073\/pnas.1904697116","article-title":"Therapeutic Genome Editing of Triple-Negative Breast Tumors Using a Noncationic and Deformable Nanolipogel","volume":"116","author":"Guo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"1","key":"2026100509320552200_cit8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12951-020-00741-z","article-title":"Emerging Nanomedicines for Effective Breast Cancer Immunotherapy [Review of Emerging Nanomedicines for Effective Breast Cancer Immunotherapy","volume":"18","author":"Bahreyni","year":"2020","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"2026100509320552200_cit9","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.3390\/ijms26073295","article-title":"PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model","volume":"26","author":"Nevala","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"2026100509320552200_cit10","doi-asserted-by":"publisher","first-page":"734853","DOI":"10.3389\/fonc.2021.734853","article-title":"Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"2026100509320552200_cit11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4143\/crt.2023.1025","article-title":"PD-L1 (SP142) Expression in Primary and Recurrent\/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance","volume":"56","author":"Han","year":"2024","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"2026100509320552200_cit12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent Advances in Targeted Strategies for Triple-Negative Breast Cancer [Review of Recent Advances in Targeted Strategies for Triple-Negative Breast Cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"2026100509320552200_cit13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70072","article-title":"Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple-Negative Breast Cancer [Review of Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple-Negative Breast Cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Thorac. Cancer"},{"key":"2026100509320552200_cit14","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.2147\/ijn.s417944","article-title":"Novel Dual-Mode NIR-II\/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer","volume":"18","author":"Liu","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"2026100509320552200_cit15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12935-025-03769-z","article-title":"Progress of PD-1\/PD-L1 Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer [Review of Progress of PD-1\/PD-L1 Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer","volume":"25","author":"Li","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"6","key":"2026100509320552200_cit16","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components [Review of Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharmaceutics"},{"issue":"36","key":"2026100509320552200_cit17","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202502540","article-title":"Lipid Nanoparticles for the Delivery of CRISPR\/Cas9 Machinery to Enable Site-Specific Integration of CFTR and Mutation-Agnostic Disease Rescue","volume":"36","author":"Foley","year":"2026","journal-title":"Adv. Funct. Mater."},{"issue":"7","key":"2026100509320552200_cit18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/ph16070970","article-title":"Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers","volume":"16","author":"Subhan","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"2026100509320552200_cit19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"2026100509320552200_cit20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.18433\/jpps30583","article-title":"Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials [Review of Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials","volume":"23","author":"Eskandari","year":"2020","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"2026100509320552200_cit21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/pharmaceutics15030831","article-title":"Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment [Review of Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment","volume":"15","author":"German-Corte\u0301s","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026100509320552200_cit22","doi-asserted-by":"publisher","first-page":"973326","DOI":"10.3389\/fbioe.2022.973326","article-title":"Delivering the CRISPR\/Cas9 System for Engineering Gene Therapies: Recent Cargo and Delivery Approaches for Clinical Translation","volume":"10","author":"Foley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"9","key":"2026100509320552200_cit23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4398","article-title":"Engineered Ionizable Lipid Nanoparticles for Targeted Delivery of RNA Therapeutics into Different Types of Cells in the Liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"issue":"02","key":"2026100509320552200_cit24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4236\/jbm.2025.132028","article-title":"Mechanisms of Targeted Drug Delivery for Liver Cancer: Active, Passive, and Subcellular Strategies","volume":"13","author":"Tian","year":"2025","journal-title":"JBM"},{"issue":"6","key":"2026100509320552200_cit25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3892\/or.2020.7791","article-title":"Lipid-based Nanoparticles for the Therapeutic Delivery of Non-coding RNAs in Breast Cancer","volume":"44","author":"Silva-Ca\u0301zares","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"2026100509320552200_cit26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-023-02083-y","article-title":"Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy [Review of Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy","volume":"21","author":"Kiaie","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"2026100509320552200_cit27","doi-asserted-by":"publisher","first-page":"214636","DOI":"10.1016\/j.bioadv.2025.214636","article-title":"Enhanced Permeability and Retention (EPR) Effect: Advances in Nanomedicine for Improved Tumor Targeting","volume":"181","author":"Khan","year":"2026","journal-title":"Biomater. Adv."},{"issue":"4","key":"2026100509320552200_cit28","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1021\/acsnano.8b08177","article-title":"Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy","volume":"13","author":"Erel-Akbaba","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"2026100509320552200_cit29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13046-019-1443-1","article-title":"Recent Advances in Nanotheranostics for Triple Negative Breast Cancer Treatment [Review of Recent Advances in Nanotheranostics for Triple Negative Breast Cancer Treatment","volume":"38","author":"Thakur","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"2026100509320552200_cit30","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","article-title":"Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides","volume":"16","author":"Moss","year":"2019","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"2026100509320552200_cit31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress [Review of Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"2026100509320552200_cit32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components [Review of Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharmaceutics"},{"issue":"11","key":"2026100509320552200_cit33","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/open.202000244","article-title":"A Cationic Stearamide-based Solid Lipid Nanoparticle for Delivering Yamanaka Factors: Evaluation of the Transfection Efficiency","volume":"9","author":"Alkan","year":"2020","journal-title":"ChemistryOpen"},{"issue":"3","key":"2026100509320552200_cit34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1101\/pdb.prot068122","article-title":"Formation of Solid Lipid Nanoparticle (SLN)\u2212Gene Vector Complexes for Transfection of Mammalian Cells In Vitro: Figure 1","volume":"2012","author":"Rudolph","year":"2012","journal-title":"Cold Spring Harb. Protoc."},{"issue":"24","key":"2026100509320552200_cit35","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.3390\/molecules25245995","article-title":"Nucleic Acid Delivery by Solid Lipid Nanoparticles Containing Switchable Lipids: Plasmid DNA vs. Messenger RNA","volume":"25","author":"Go\u0301mez-Aguado","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"2026100509320552200_cit36","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1039\/D2NA00795A","article-title":"Lipid-Based Colloidal Nanoparticles for Applications in Targeted Vaccine Delivery","volume":"5","author":"Khan","year":"2023","journal-title":"Nanoscale Adv."},{"issue":"1","key":"2026100509320552200_cit37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.30714\/j-ebr.2021165779","article-title":"Optimization and Screening of Solid Lipid Nanoparticle Production for Gene Delivery by Factorial Design and Response Surface Methodology","volume":"4","author":"Akbaba","year":"2021","journal-title":"Exp. Biomed. Res."},{"issue":"7","key":"2026100509320552200_cit38","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1021\/acs.molpharmaceut.5c00139","article-title":"Quality-by-Design-Assisted Laboratory Scale-Up of Lipid Nanoparticles of Stearic Acid\u2212Raloxifene Hydrochloride Conjugate: A Pathway for Enhanced Oral Bioavailability via Lymphatic Uptake","volume":"22","author":"Mourya","year":"2025","journal-title":"Mol. Pharmaceutics"},{"issue":"10","key":"2026100509320552200_cit39","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41557-024-01584-z","article-title":"Engineering a Nanoscale Liposome-in-Liposome for in Situ Biochemical Synthesis and Multi-Stage Release","volume":"16","author":"Pilkington","year":"2024","journal-title":"Nat. Chem."},{"issue":"15","key":"2026100509320552200_cit40","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3390\/polym15153181","article-title":"Advanced Particle Size Analysis in High-Solid-Content Polymer Dispersions Using Photon Density Wave Spectroscopy","volume":"15","author":"Schlappa","year":"2023","journal-title":"Polymers"},{"key":"2026100509320552200_cit41","doi-asserted-by":"publisher","first-page":"1241368","DOI":"10.3389\/fmedt.2023.1241368","article-title":"Feasibility of the Preparation of Cochleate Suspensions from Naturally Derived Phosphatidylserines","volume":"5","author":"Kristensen","year":"2023","journal-title":"Front. Med. Technol."},{"issue":"11","key":"2026100509320552200_cit42","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome Engineering Using the CRISPR-Cas9 System","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"17","key":"2026100509320552200_cit43","doi-asserted-by":"publisher","first-page":"16412","DOI":"10.1021\/acsnano.2c12261","article-title":"Nonviral In Vivo Delivery of CRISPR-Cas9 Using Protein-Agnostic, High-Loading Porous Silicon and Polymer Nanoparticles","volume":"17","author":"Fletcher","year":"2023","journal-title":"ACS Nano"},{"key":"2026100509320552200_cit44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jddst.2018.01.001","article-title":"Development and Evaluation of Antisense shRNA-Encoding Plasmid Loaded Solid Lipid Nanoparticles against 5-\u03b1 Reductase Activity","volume":"44","author":"Akbaba","year":"2018","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"12","key":"2026100509320552200_cit45","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2217\/nnm-2020-0412","article-title":"Special Focus Issue Part II: Recruitment of Solid Lipid Nanoparticles for the Delivery of CRISPR\/Cas9: Primary Evaluation of Anticancer Gene Editing","volume":"16","author":"Akbaba","year":"2021","journal-title":"Nanomedicine"},{"key":"2026100509320552200_cit46","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20230147","volume-title":"A Perspective of Lipid Nanoparticles for RNA Delivery","author":"Ma","year":"2024"},{"issue":"4","key":"2026100509320552200_cit47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.gt.3300863","article-title":"Lipoplex Size Is a Major Determinant of in Vitro Lipofection Efficiency","volume":"6","author":"Ross","year":"1999","journal-title":"Gene Ther."},{"issue":"3","key":"2026100509320552200_cit48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2013.07.024","article-title":"The Effects of Lipoplex Formulation Variables on the Protein Corona and Comparisons with in Vitro Transfection Efficiency","volume":"171","author":"Betker","year":"2013","journal-title":"J. Controlled Release"},{"issue":"5","key":"2026100509320552200_cit49","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1039\/D3BM01629C","article-title":"A Quaternary Ammonium-Based Nanosystem Enables Delivery of CRISPR\/Cas9 for Cancer Therapy","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomater. Sci."},{"key":"2026100509320552200_cit50","volume-title":"The Guidelines for Standards of Care in Animal Shelters","author":"Association of Shelter Veterinarians","year":"2022","edition":"2"},{"key":"2026100509320552200_cit51","doi-asserted-by":"publisher","first-page":"108631","DOI":"10.1016\/j.pharmthera.2024.108631","article-title":"Orthotopic and Metastatic Tumour Models in Preclinical Cancer Research","volume":"257","author":"Stribbling","year":"2024","journal-title":"Pharmacol. Ther."},{"issue":"34","key":"2026100509320552200_cit52","doi-asserted-by":"publisher","first-page":"2103347","DOI":"10.1002\/adfm.202103347","article-title":"Bioinert, Stealth or Interactive: How Surface Chemistry of Nanocarriers Determines Their Fate In Vivo","volume":"31","author":"Friedl","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"5","key":"2026100509320552200_cit53","doi-asserted-by":"publisher","first-page":"051406","DOI":"10.1103\/PhysRevE.70.051406","article-title":"Hydrodynamics and Electrokinetics of Spherical Liposomes with Coatings of Terminally Anchored Poly(Ethylene Glycol): Numerically Exact Electrokinetics with Self-Consistent Mean-Field Polymer","volume":"70","author":"Hill","year":"2004","journal-title":"Phys. Rev. E:Stat., Nonlinear, Soft Matter Phys."},{"issue":"1","key":"2026100509320552200_cit54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12896-025-01023-y","article-title":"Preparation and Characterization of a iRGD-Modified Recombinant Spider Silk Particles for Antitumor Polypeptide Drug Delivery into Cancer Cells","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Biotechnol."},{"issue":"22","key":"2026100509320552200_cit55","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.3390\/polym17222979","article-title":"PEGylation Enhances Colloidal Stability and Promotes Ligand-Mediated Targeting of LAF\u2212Xenopeptide mRNA Complexes","volume":"17","author":"Folda","year":"2025","journal-title":"Polymers"},{"issue":"48","key":"2026100509320552200_cit56","doi-asserted-by":"publisher","first-page":"46101","DOI":"10.1021\/acsomega.3c07138","article-title":"Design of Liposome Formulations for CRISPR\/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders","volume":"8","author":"Akbaba","year":"2023","journal-title":"ACS Omega"},{"key":"2026100509320552200_cit57","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.2147\/ijn.s321071","article-title":"Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles","volume":"16","author":"Huang","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"2026100509320552200_cit58","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41467-021-21858-1","article-title":"Tumor-Penetrating Therapy for \u03925 Integrin-Rich Pancreas Cancer","volume":"12","author":"Hurtado De Mendoza","year":"2021","journal-title":"Nat. Commun."},{"key":"2026100509320552200_cit59","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.2147\/ijn.s321071","article-title":"Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles","volume":"16","author":"Huang","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"2026100509320552200_cit60","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1021\/acsbiomaterials.4c00160","article-title":"Membrane-Cloaked Nanoparticles for RNA Interference of \u03b2-Catenin in Triple-Negative Breast Cancer","volume":"10","author":"Scully","year":"2024","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2026100509320552200_cit61","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16006","article-title":"PCMT1 Knockdown Attenuates Malignant Properties by Globally Regulating Transcriptome Profiles in Triple-Negative Breast Cancer Cells","volume":"11","author":"Saiding","year":"2023","journal-title":"PeerJ"},{"issue":"7","key":"2026100509320552200_cit62","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms24076420","article-title":"PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression","volume":"24","author":"Alkaabi","year":"2023","journal-title":"IJMS"},{"issue":"6","key":"2026100509320552200_cit63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-018-0267-9","article-title":"Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Therapeutics","volume":"20","author":"Givens","year":"2018","journal-title":"AAPS J."},{"key":"2026100509320552200_cit64","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.addr.2023.114990","article-title":"Lipid Nanoparticles (LNPs) for in Vivo RNA Delivery and Their Breakthrough Technology for Future Applications","volume":"200","author":"Jeong","year":"2023","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026100509320552200_cit65","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid Nanoparticles for mRNA Delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"3","key":"2026100509320552200_cit66","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s44222-023-00138-1","article-title":"Controlling the Biodistribution and Clearance of Nanomedicines","volume":"2","author":"Cabral","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"issue":"9","key":"2026100509320552200_cit67","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s44222-024-00203-3","article-title":"Nanoparticle Delivery to Tumours: From EPR and ATR Mechanisms to Clinical Impact","volume":"2","author":"Dasgupta","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"5","key":"2026100509320552200_cit68","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.nano.2017.03.002","article-title":"Effect of Particle Size on the Biodistribution, Toxicity, and Efficacy of Drug-Loaded Polymeric Nanoparticles in Chemoradiotherapy","volume":"13","author":"Caster","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"2026100509320552200_cit69","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.jddst.2025.106694","article-title":"A Synergistic Microemulsion Approach with Cetyl Myristoleate and Hyaluronic Acid for Enhanced Osteoarthritis Therapy: In Vitro and in Vivo Evaluation","volume":"106","author":"C\u0327ag\u0306lar","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"5","key":"2026100509320552200_cit70","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1039\/d5pm00109a","article-title":"Solid Lipid Nanoparticles in Cervical Cancer: A Comprehensive Review of a Decade of Progress and Prospects","volume":"2","author":"Tiwary","year":"2025","journal-title":"RSC Pharm."},{"key":"2026100509320552200_cit71","doi-asserted-by":"publisher","first-page":"125881","DOI":"10.1016\/j.ijpharm.2025.125","article-title":"Effect of Positive Charges on Liposome Stability, Uptake Efficacy and Impact on Cells","volume":"681","author":"Zhao","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026100509320552200_cit72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/btm2.10120","article-title":"Uptake and Function of Membrane-destabilizing Cationic Nanogels for Intracellular Drug Delivery","volume":"4","author":"Liechty","year":"2019","journal-title":"Bioeng. Transl. Med."},{"issue":"1","key":"2026100509320552200_cit73","doi-asserted-by":"publisher","first-page":"13508","DOI":"10.1038\/s41598-022-17752-5","article-title":"Enhancing Nanoparticle Accumulation in Two Dimensional, Three Dimensional, and Xenograft Mouse Cancer Cell Models in the Presence of Docetaxel","volume":"12","author":"Bromma","year":"2022","journal-title":"Sci. Rep."},{"key":"2026100509320552200_cit74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-0716-1892-9_18","article-title":"Design and Preparation of Solid Lipid Nanoparticle (SLN)-Mediated DNA Vaccines","volume-title":"Vaccine Design","author":"Francis","year":"2022"},{"issue":"15","key":"2026100509320552200_cit75","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cells14151136","article-title":"Nanotechnology-Based Delivery of CRISPR\/Cas9 for Cancer Treatment: A Comprehensive Review","volume":"14","author":"Rauf","year":"2025","journal-title":"Cells"},{"issue":"1","key":"2026100509320552200_cit76","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s42003-022-04385-7","article-title":"Tumor-Specific Intracellular Delivery: Peptide-Guided Transport of a Catalytic Toxin","volume":"6","author":"Allred","year":"2023","journal-title":"Commun. Biol."},{"key":"2026100509320552200_cit77","doi-asserted-by":"publisher","first-page":"123511","DOI":"10.1016\/j.biomaterials.2025.123511","article-title":"Nanoparticles-Mediated Intratumoral Gene Editing Targeting PD-L1 and Galectin-9 for Improved Cancer Immunotherapy","volume":"324","author":"Fang","year":"2026","journal-title":"Biomaterials"},{"issue":"18","key":"2026100509320552200_cit78","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1021\/bi9602019","article-title":"Mechanism of DNA Release from Cationic Liposome\/DNA Complexes Used in Cell Transfection","volume":"35","author":"Xu","year":"1996","journal-title":"Biochemistry"},{"issue":"21","key":"2026100509320552200_cit79","doi-asserted-by":"publisher","first-page":"11493","DOI":"10.1073\/pnas.93.21.11493","article-title":"Mechanism of Oligonucleotide Release from Cationic Liposomes","volume":"93","author":"Zelphati","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"2026100509320552200_cit80","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1039\/D0BM01947J","article-title":"Illuminating Endosomal Escape of Polymorphic Lipid Nanoparticles That Boost mRNA Delivery","volume":"9","author":"Herrera","year":"2021","journal-title":"Biomater. Sci."},{"issue":"1","key":"2026100509320552200_cit81","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1038\/s41467-024-46533-z","article-title":"An Antifouling Membrane-Fusogenic Liposome for Effective Intracellular Delivery in Vivo","volume":"15","author":"Kong","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026100509320552200_cit82","doi-asserted-by":"publisher","first-page":"20220517","DOI":"10.1515\/ntrev-2022-0517","article-title":"Solid Lipid Nanoparticles for Targeted Natural and Synthetic Drugs Delivery in High-Incidence Cancers, and Other Diseases: Roles of Preparation Methods, Lipid Composition, Transitional Stability, and Release Profiles in Nanocarriers\u2019 Development","volume":"12","author":"Mohammed","year":"2023","journal-title":"Nanotechnol. Rev."},{"key":"2026100509320552200_cit83","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jprot.2015.02.009","article-title":"Surface Chemistry and Serum Type Both Determine the Nanoparticle\u2212Protein Corona","volume":"119","author":"Pozzi","year":"2015","journal-title":"J. Proteomics"},{"issue":"1","key":"2026100509320552200_cit84","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1038\/s41598-020-62848-5","article-title":"Optimization of Cell Viability Assays to Improve Replicability and Reproducibility of Cancer Drug Sensitivity Screens","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"2026100509320552200_cit85","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/cancers15082366","article-title":"Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies","volume":"15","author":"Nahar","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"2026100509320552200_cit86","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms24076420","article-title":"PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression","volume":"24","author":"Alkaabi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026100509320552200_cit87","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/ol.2022.13596","article-title":"Research Progress on the Intrinsic Non-immune Function of PD-L1 in Tumors (Review)","volume":"25","author":"Deng","year":"2022","journal-title":"Oncol. Lett."},{"issue":"3","key":"2026100509320552200_cit88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells [Review of Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"2026100509320552200_cit89","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41419-024-06943-9","article-title":"ALDH1A1 Promotes Immune Escape of Tumor Cells through ZBTB7B-Glycolysis Pathway","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"12","key":"2026100509320552200_cit90","doi-asserted-by":"publisher","first-page":"985","DOI":"10.20892\/j.issn.2095-3941.2023.0333","article-title":"Cancer Stem Cells: A Target for Overcoming Therapeutic Resistance and Relapse [Review of Cancer Stem Cells: A Target for Overcoming Therapeutic Resistance and Relapse","volume":"20","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"2026100509320552200_cit91","doi-asserted-by":"publisher","first-page":"102717","DOI":"10.1016\/j.omtn.2025.102717","article-title":"Exploring CRISPR-Cas: The Transformative Impact of Gene Editing in Molecular Biology","volume":"36","author":"Pandey","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"2026100509320552200_cit92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287733","article-title":"Generation of Murine Tumor Models Refractory to \u03b1PD-1\/-L1 Therapies Due to Defects in Antigen Processing\/Presentation or IFN\u03b3 Signaling Using CRISPR\/Cas9","volume":"19","author":"Chariou","year":"2024","journal-title":"PLoS One"},{"issue":"642","key":"2026100509320552200_cit93","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of Interleukin-2 Overcomes Resistance to Neoadjuvant CTLA4 and PD1 Blockade in Ex Vivo Patient Tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"2026100509320552200_cit94","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.7150\/jca.108163","article-title":"Strategies to Overcome PD-1\/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades","volume":"16","author":"Liu","year":"2025","journal-title":"J. Cancer"},{"issue":"1","key":"2026100509320552200_cit95","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the Breast Tumor Immune Microenvironment: Cold-to-Hot Transition for Enhanced Immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"19","key":"2026100509320552200_cit96","doi-asserted-by":"publisher","first-page":"10712","DOI":"10.3390\/ijms251910712","article-title":"Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer","volume":"25","author":"Llaguno-Munive","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"2026100509320552200_cit97","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/ijms23031665","article-title":"Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC [Review of Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC","volume":"23","author":"Ferrari","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026100509320552200_cit98","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1038\/s41467-023-42883-2","article-title":"Inhibition of Glycolysis-Driven Immunosuppression with a Nano-Assembly Enhances Response to Immune Checkpoint Blockade Therapy in Triple Negative Breast Cancer","volume":"14","author":"Ren","year":"2023","journal-title":"Nat. Commun."},{"issue":"22","key":"2026100509320552200_cit99","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.3390\/cancers16223768","article-title":"Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems","volume":"16","author":"Nikitovic","year":"2024","journal-title":"Cancers"},{"key":"2026100509320552200_cit100","doi-asserted-by":"publisher","first-page":"1455211","DOI":"10.3389\/fimmu.2024.1455211","article-title":"Remodeling of Tumour Microenvironment: Strategies to Overcome Therapeutic Resistance and Innovate Immunoengineering in Triple-Negative Breast Cancer [Review of Remodeling of Tumour Microenvironment: Strategies to Overcome Therapeutic Resistance and Innovate Immunoengineering in Triple-Negative Breast Cancer","volume":"15","author":"Singh","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"2026100509320552200_cit101","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12951-021-00947-9","article-title":"Amplified Antitumor Efficacy by a Targeted Drug Retention and Chemosensitization Strategy-Based \u201cCombo\u201d Nanoagent Together with PD-L1 Blockade in Reversing Multidrug Resistance","volume":"19","author":"Jiang","year":"2021","journal-title":"J. Nanobiotechnol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00750","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5069\/68442909\/mp6c00750.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5069\/68442909\/mp6c00750.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:33Z","timestamp":1791208173000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/5069\/5426101\/Reinforcement-of-Solid-Lipid-Nanoparticles-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":101,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00750","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}